P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY

Documenti analoghi

• Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
  di: Amer M. Zeidan, et al.
  Pubblicazione: (2024-07-01)
• P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
  di: Amer M. Zeidan, et al.
  Pubblicazione: (2023-08-01)
• The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
  di: Robert Briski, et al.
  Pubblicazione: (2023-10-01)
• Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
  di: John Paul Yun, et al.
  Pubblicazione: (2023-08-01)
• Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome
  di: Portia Smallbone, et al.
  Pubblicazione: (2025-02-01)